Aqua Pharmaceuticals has added low-potency foam corticosteroid to its dermatology portfolio with the acquisition of US rights and re-launch of Verdeso (desonide) Foam, 0.05% from Stiefel, a GSK company. Indicated for the topical treatment ...
Validus Pharmaceuticals and Wood Creek Capital Management have acquired the US rights to six product lines from Novartis Pharmaceuticals Corporation (NPC). The acquired six product lines include Lopressor (metoprolol tartrate USP) ...